Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 5
1994 2
1995 10
1996 6
1997 13
1998 9
1999 20
2000 17
2001 13
2002 19
2003 16
2004 27
2005 23
2006 18
2007 15
2008 15
2009 18
2010 11
2011 17
2012 18
2013 16
2014 14
2015 19
2016 6
2017 7
2018 9
2019 5
2020 5
2021 2
2022 2
2023 6
2024 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

354 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S; RENAAL Study Investigators. Brenner BM, et al. N Engl J Med. 2001 Sep 20;345(12):861-9. doi: 10.1056/NEJMoa011161. N Engl J Med. 2001. PMID: 11565518 Free article. Clinical Trial.
The composite of morbidity and mortality from cardiovascular causes was similar in the two groups, although the rate of first hospitalization for heart failure was significantly lower with losartan (risk reduction, 32 percent; P=0.005). The level of proteinuria decl …
The composite of morbidity and mortality from cardiovascular causes was similar in the two groups, although the rate of first hospitalizatio …
The role of losartan in the management of patients with heart failure.
Dickstein K. Dickstein K. Clin Ther. 2001 Sep;23(9):1456-77. doi: 10.1016/s0149-2918(01)80120-x. Clin Ther. 2001. PMID: 11589260 Review.
OBJECTIVE: This review summarizes existing data on losartan, an angiotensin II (AII)-receptor antagonist, and compares its potential role with that of ACE inhibitors in the management of patients with heart failure. ...CONCLUSIONS: There is strong evidence for the b …
OBJECTIVE: This review summarizes existing data on losartan, an angiotensin II (AII)-receptor antagonist, and compares its potential …
Comparative clinical- and cost-effectiveness of candesartan and losartan in the management of hypertension and heart failure: a systematic review, meta- and cost-utility analysis.
Grosso AM, Bodalia PN, Macallister RJ, Hingorani AD, Moon JC, Scott MA. Grosso AM, et al. Int J Clin Pract. 2011 Mar;65(3):253-63. doi: 10.1111/j.1742-1241.2011.02633.x. Epub 2011 Feb 1. Int J Clin Pract. 2011. PMID: 21284790 Review.
Heart failure: composite of cardiovascular death and hospital admission for management of heart failure. ...We could find no robust evidence supporting the superiority of candesartan over losartan in the treatment of heart failure. We therefore recomme …
Heart failure: composite of cardiovascular death and hospital admission for management of heart failure. ...We could find no r …
Losartan in heart failure. Hemodynamic effects and tolerability. Losartan Hemodynamic Study Group.
Crozier I, Ikram H, Awan N, Cleland J, Stephen N, Dickstein K, Frey M, Young J, Klinger G, Makris L, et al. Crozier I, et al. Circulation. 1995 Feb 1;91(3):691-7. doi: 10.1161/01.cir.91.3.691. Circulation. 1995. PMID: 7828295 Clinical Trial.
BACKGROUND: The aim of the present study was to assess the short- and long-term effects of multiple doses of the angiotensin II receptor antagonist losartan in heart failure. METHODS AND RESULTS: A multicenter, placebo-controlled, oral, multidose (2.5, 10, 25, and 5 …
BACKGROUND: The aim of the present study was to assess the short- and long-term effects of multiple doses of the angiotensin II receptor ant …
Losartan improves heart rate variability and heart rate turbulence in heart failure due to ischemic cardiomyopathy.
Ozdemir M, Arslan U, Türkoğlu S, Balcioğlu S, Cengel A. Ozdemir M, et al. J Card Fail. 2007 Dec;13(10):812-7. doi: 10.1016/j.cardfail.2007.08.002. J Card Fail. 2007. PMID: 18068613 Clinical Trial.
BACKGROUND: Heart rate variability (HRV) and heart rate turbulence are known to be disturbed and associated with excess mortality in heart failure. ...CONCLUSIONS: A 12-week-long losartan therapy significantly improved HRV and heart rate turbule …
BACKGROUND: Heart rate variability (HRV) and heart rate turbulence are known to be disturbed and associated with excess mortal …
Angiotensin II receptor antagonists in heart failure: rationale and design of the evaluation of losartan in the elderly (ELITE) trial.
Pitt B, Chang P, Timmermans PB. Pitt B, et al. Cardiovasc Drugs Ther. 1995 Oct;9(5):693-700. doi: 10.1007/BF00878552. Cardiovasc Drugs Ther. 1995. PMID: 8573552 Review.
It is possible to inhibit the effect of angiotensin II without increasing bradykinin levels using an angiotensin II type I blocking agent such as losartan. How effective losartan is compared with an ACE-I is uncertain, however. Some of the beneficial effects of ACE- …
It is possible to inhibit the effect of angiotensin II without increasing bradykinin levels using an angiotensin II type I blocking agent su …
Effects of Losartan on Patients Hospitalized for Acute COVID-19: A Randomized Controlled Trial.
Tran KC, Asfar P, Cheng M, Demiselle J, Singer J, Lee T, Sweet D, Boyd J, Walley K, Haljan G, Sharif O, Geri G, Auchabie J, Quenot JP, Lee TC, Tsang J, Meziani F, Lamontagne F, Dubee V, Lasocki S, Ovakim D, Wood G, Turgeon A, Cohen Y, Lebas E, Goudelin M, Forrest D, Teale A, Mira JP, Fowler R, Daneman N, Adhikari NKJ, Gousseff M, Leroy P, Plantefeve G, Rispal P, Courtois R, Winston B, Reynolds S, Birks P, Bienvenu B, Tadie JM, Talarmin JP, Ansart S, Russell JA; ARBs CORONA II Team. Tran KC, et al. Clin Infect Dis. 2024 Sep 26;79(3):615-625. doi: 10.1093/cid/ciae306. Clin Infect Dis. 2024. PMID: 39325643 Free PMC article. Clinical Trial.
We aimed to evaluate the effect of losartan versus usual care on 28-day mortality in patients hospitalized for acute COVID-19. ...RESULTS: The trial was stopped early because of a serious safety concern with losartan. In 341 patients, any SAE and hypotension were si …
We aimed to evaluate the effect of losartan versus usual care on 28-day mortality in patients hospitalized for acute COVID-19. ...RES …
Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE).
Pitt B, Segal R, Martinez FA, Meurers G, Cowley AJ, Thomas I, Deedwania PC, Ney DE, Snavely DB, Chang PI. Pitt B, et al. Lancet. 1997 Mar 15;349(9054):747-52. doi: 10.1016/s0140-6736(97)01187-2. Lancet. 1997. PMID: 9074572 Clinical Trial.
BACKGROUND: To determine whether specific angiotensin II receptor blockade with losartan offers safety and efficacy advantages in the treatment of heart failure over angiotensin-converting-enzyme (ACE) inhibition with captopril, the ELITE study compared losartan …
BACKGROUND: To determine whether specific angiotensin II receptor blockade with losartan offers safety and efficacy advantages in the …
Safety and efficacy of losartan for the reduction of brain atrophy in clinically diagnosed Alzheimer's disease (the RADAR trial): a double-blind, randomised, placebo-controlled, phase 2 trial.
Kehoe PG, Turner N, Howden B, Jarutyte L, Clegg SL, Malone IB, Barnes J, Nielsen C, Sudre CH, Wilson A, Thai NJ, Blair PS, Coulthard E, Lane JA, Passmore P, Taylor J, Mutsaerts HJ, Thomas DL, Fox NC, Wilkinson I, Ben-Shlomo Y; RADAR investigators. Kehoe PG, et al. Lancet Neurol. 2021 Nov;20(11):895-906. doi: 10.1016/S1474-4422(21)00263-5. Lancet Neurol. 2021. PMID: 34687634 Free PMC article. Clinical Trial.
We investigated whether the angiotensin II receptor antagonist losartan, compared with placebo, could reduce brain volume loss, as a measure of disease progression, in clinically diagnosed mild-to-moderate Alzheimer's disease. ...The number of adverse events was low (22 in …
We investigated whether the angiotensin II receptor antagonist losartan, compared with placebo, could reduce brain volume loss, as a …
Effects of losartan versus captopril on mortality in patients with symptomatic heart failure: rationale, design, and baseline characteristics of patients in the Losartan Heart Failure Survival Study--ELITE II.
Pitt B, Poole-Wilson P, Segal R, Martinez FA, Dickstein K, Camm AJ, Konstam MA, Riegger G, Klinger GH, Neaton J, Sharma D, Thiyagarajan B. Pitt B, et al. J Card Fail. 1999 Jun;5(2):146-54. doi: 10.1016/s1071-9164(99)90037-4. J Card Fail. 1999. PMID: 10404354 Clinical Trial.
BACKGROUND: In the Evaluation of Losartan in the Elderly (ELITE) heart failure study, a survival benefit (primarily because of a reduction in sudden deaths) was observed in symptomatic patients treated with losartan compared with captopril. METHODS AND RESULT …
BACKGROUND: In the Evaluation of Losartan in the Elderly (ELITE) heart failure study, a survival benefit (primarily because of …
354 results

Searches related to "losartan heart"